% Expired Patents = 50.0

Forward Citations = 39

Loading Chart...

11 inventors (with patents filed for the assignee):

Hyun-Soo Kim (3 out of 160 patents)

Kyung-Bock Lee (2 out of 2 patents)

Gwang Hwan Lee (1 out of 27 patents)

4. Hee-Hoon Yoon (1 out of 4 patents)

5. Young-Mo Kang (1 out of 1 patent)

6. Sang-Kyo Park (1 out of 1 patent)

7. Sang-Kap Lee (1 out of 1 patent)

8. Hugh-Chul Kim (1 out of 1 patent)

9. Hong Ki Jun (1 out of 1 patent)

10. Young Hwan Ahn (1 out of 1 patent)

11. Ki Ho Park (1 out of 1 patent)

4 patents: Sort by Forward Citations

1. 7635591 - Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease (2009-12-22),

2. 7390800 - [object Object] (2008-06-24),

3. 7390658 - [object Object] (2008-06-24),

4. 7229827 - Method for differentiating mesenchymal stem cells into neural cells (2007-06-12),

Company Overview

Fcb-pharmicell Co., Ltd. is a leading biotechnology company specializing in cell therapy and regenerative medicine. With cutting-edge technologies and innovative research, we develop advanced treatments for various diseases. Our focus is on providing personalized therapies to improve patients' quality of life.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

4 Patents

#103 in

#2,202 in South Korea

KR

Fcb-Pharmicell Co., Ltd.

Forward Citations = 39

11 inventors:

Hyun-Soo Kim (3 out of 160 patents)

Kyung-Bock Lee (2 out of 2 patents)

Gwang Hwan Lee (1 out of 27 patents)

4. Hee-Hoon Yoon (1 out of 4 patents)

5. Young-Mo Kang (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Fcb-Pharmicell Co., Ltd.. Retrieved from https://idiyas.com/company/fcb-pharmicell-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]